Abstract: Compounds of formula (I): and related aspects.

Abstract: Compounds of formula (I): (I) and related aspects.

Abstract: A coolant pump includes an impeller pump wheel, a pump housing defining an outlet volute, and an outlet valve arrangement. The pump housing comprises an outlet volute housing which defines a first outlet channel comprising a valve opening. The valve opening is defined by a valve seat which defines a valve seat plane and a symmetry plane. The symmetry plane is arranged in the middle of and rectangular to the valve seat plane. The outlet valve arrangement is in the first outlet channel and comprises a valve flap which opens/closes the valve opening. The valve flap comprises a flap seat corresponding to the valve seat. The valve flap rotates around a pivot axis parallel to the symmetry plane and having an eccentricity from the symmetry plane which is between 1/20 and 1/1 of a distance of the pivot axis to the valve seat plane when the valve flap is open.

Abstract: A coolant pump includes an outlet volute comprising a pivot axis, an impeller pump, a housing, and an outlet valve arrangement. The housing comprises an outlet volute housing defining the outlet volute and comprises a volute housing wall comprising a recess, and a first outlet channel comprising a valve opening. The outlet valve arrangement is disposed in the first outlet channel and comprises a valve body which opens or closes the valve opening. The valve body comprises a circle segment body comprising a proximal surface and a maximum outside radius. The circle segment body is rotated around the pivot axis. The proximal surface is distant from the pivot axis by an offset distance which is at least ¼ of the maximum outside radius. The recess houses the circle segment body in the closed valve position. A lateral distance of the pivot axis to the volute housing wall is approximately equal to the offset distance.

Abstract: A coolant pump includes an outlet volute comprising a pivot axis, an impeller pump, a housing, and an outlet valve arrangement. The housing comprises an outlet volute housing defining the outlet volute and comprises a volute housing wall comprising a recess, and a first outlet channel comprising a valve opening. The outlet valve arrangement is disposed in the first outlet channel and comprises a valve body which opens or closes the valve opening. The valve body comprises a circle segment body comprising a proximal surface and a maximum outside radius. The circle segment body is rotated around the pivot axis. The proximal surface is distant from the pivot axis by an offset distance which is at least ¼ of the maximum outside radius. The recess houses the circle segment body in the closed valve position. A lateral distance of the pivot axis to the volute housing wall is approximately equal to the offset distance.

Abstract: A coolant pump includes an impeller pump wheel, a pump housing defining an outlet volute, and an outlet valve arrangement. The pump housing comprises an outlet volute housing which defines a first outlet channel comprising a valve opening. The valve opening is defined by a valve seat which defines a valve seat plane and a symmetry plane. The symmetry plane is arranged in the middle of and rectangular to the valve seat plane. The outlet valve arrangement is in the first outlet channel and comprises a valve flap which opens/closes the valve opening. The valve flap comprises a flap seat corresponding to the valve seat. The valve flap rotates around a pivot axis parallel to the symmetry plane and having an eccentricity from the symmetry plane which is between 1/20 and 1/1 of a distance of the pivot axis to the valve seat plane when the valve flap is open.

Abstract: The invention relates to the 6-cycloamino-3-(pyridin-4-yl)imidazo[I,2-b]pyridazine derivatives corresponding to general formula (I): Wherein R2, R3, R7, R8, A, L and B are as defined herein. Also disclosed are the preparative methods and therapeutic use thereof.

Abstract: The invention relates to derivatives of 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine and 6-cycloamino-2-furanyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine with general formula (I). The invention also relates to a method for the preparation and therapeutic application thereof, in the treatment or prevention of illnesses involving casein kinase 1 epsilon and/or casein kinase 1 delta.

Abstract: The invention relates to the 6-cycloamino-3-(pyridin-4-yl)imidazo[I,2-b]pyridazine derivatives corresponding to general formula (I): Wherein R2, R3, R7, R8, A, L and B are as defined herein. Also disclosed are the preparative methods and therapeutic use thereof.

Abstract: The invention relates to the 6-cycloamino-3-(pyridin-4-yl)imidazo[I,2-b]pyridazine derivatives corresponding to general formula (I): Wherein R2, R3, R7, R8, A, L and B are as defined herein. Also disclosed are the preparative methods and therapeutic use thereof.

Abstract: The invention relates to the 6-cycloamino-3-(pyridin-4-yl)imidazo[I,2-b]pyridazine derivatives corresponding to general formula (I): Wherein R2, R3, R7, R8, A, L and B are as defined herein. Also disclosed are the preparative methods and therapeutic use thereof.

Abstract: A material controllingly releases by evaporation a liquid active substance and comprises a polymer material matrix impregnated with a liquid composition. The liquid composition contains a mixture of the active substance and a solute which reduces the active substance evaporation kinetics by decreasing a vapor pressure. A method for producing the material and an accessory comprising an element made therefrom are also described.

Abstract: The invention relates to a compound of formula (I): Wherein R1, R2, R3 and R4 are as defined herein. The invention also relates to methods of preparation of compounds of formula (I) as well as to their therapeutic application.

Abstract: The invention relates to therapeutic uses of a dihydrospiro-[cycloalkyl]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, m, n, p and q are as described herein. Specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3?, such as Alzheimer disease.

Abstract: The invention relates to a compound of formula (I): Wherein R1, R2, R3 and R4 are as defined herein. The invention also relates to methods of preparation of compounds of formula (I) as well as to their therapeutic application.

Abstract: The invention relates to a compound of formula (I): Wherein R1, R2, R3 and R4 are as defined herein. The invention also relates to methods of preparation of compounds of formula (I) as well as to their therapeutic application.

Abstract: The invention relates to therapeutic uses of a dihydrospiro-[cycloalkyl]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, m, n, p and q are as described herein. Specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3?, such as Alzheimer disease.

Abstract: The invention relates to a dihydrospiro-[cycloalkyl]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, m, n, p and q are as described herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3?, such as Alzheimer disease.